country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-148640

Copy Link Print Information

WK500B

WK500B is a potent and orally active BCL6 inhibitor with a K_D of 1.61 μM. WK500B engages intracellular BCL6 and disrupts BCL6‑corepressor interactions to reactivate BCL6 target genes. WK500B exerts cytotoxicity against diffuse large B‑cell lymphoma cells and induces apoptosis and cell cycle arrest. WK500B suppresses germinal center formation in C57BL/6 mice and DLBCL tumor growth in SCID xenograft models without observable toxicity. WK500B can be used for the study of diffuse large B‑cell lymphoma (DLBCL).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 2253985-29-2
分子式: C₂₂H₂₃BrFN₇O
分子量:500.38

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

WK500B 構造式

CAS 番号: 2253985-29-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- Parmacokinetics
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

CXCR4

Histone Methyltransferase アイソフォーム固有の製品をすべて表示 :

CXCR アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
DOHH-2	IC₅₀	1100 nM Compound: 13; WK500B	Antitumor activity against BCL6 dependent human DOHH-2 cells assessed as cell growth inhibition Antitumor activity against BCL6 dependent human DOHH-2 cells assessed as cell growth inhibition	[PMID: 36441945]
Farage	IC₅₀	1100 nM Compound: 13; WK500B	Antitumor activity against BCL6 dependent human Farage cells assessed as cell growth inhibition Antitumor activity against BCL6 dependent human Farage cells assessed as cell growth inhibition	[PMID: 36441945]
L02	IC₅₀	21.61 μM Compound: 13; WK500B	Antitumor activity against human L02 cells assessed as cell growth inhibition Antitumor activity against human L02 cells assessed as cell growth inhibition	[PMID: 36441945]
OCI-Ly7	IC₅₀	1100 nM Compound: 13; WK500B	Antitumor activity against BCL6 dependent human OCILY7 cells assessed as cell growth inhibition Antitumor activity against BCL6 dependent human OCILY7 cells assessed as cell growth inhibition	[PMID: 36441945]
SUD4	IC₅₀	1.39 μM Compound: 13; WK500B	Antitumor activity against BCL6 dependent human SU-DHL-4 cells assessed as cell growth inhibition Antitumor activity against BCL6 dependent human SU-DHL-4 cells assessed as cell growth inhibition	[PMID: 36441945]
SU-DHL-6	IC₅₀	1100 nM Compound: 13; WK500B	Antitumor activity against BCL6 dependent human SU-DHL-6 cells assessed as cell growth inhibition Antitumor activity against BCL6 dependent human SU-DHL-6 cells assessed as cell growth inhibition	[PMID: 36441945]

体外実験

WK500B (2.5-10 μM; 24 h) dose-dependently and specifically inhibits BCL6 BTB domain-mediated transcriptional repression in 293T cells, with near-complete inhibition at 10 μM^[1].
WK500B (2.5-10 μM; 24 h) can reactivate BCL6 target genes (p53, CDKN1A, CXCR4, CD69) in BCL6-dependent SUDHL4 and Farage DLBCL cells in a dose-dependent and specific manner, but has no such effect in Toledo cells that do not express BCL6^[1].
WK500B directly binds to the purified BCL6 BTB protein with a K_D of 1.61 μM and inhibits the interaction between purified BCL6 BTB protein and SMRT peptide with an IC₅₀ of 1.37 μM^[1].
WK500B (24 h) disrupts the colocalization of BCL6 and its corepressor SMRT in SUDHL4 DLBCL cells^[1].
WK500B (2.5-10 μM; 24 h) can induce dose-dependent S-phase cell cycle arrest in SUDHL4 diffuse large B-cell lymphoma (DLBCL) cells, with 78% of cells in S phase at a concentration of 10 μM; it can also induce dose-dependent apoptosis, with an apoptosis rate of 66.0% at 10 μM^[1].
WK500B (1.25-10 μM; 72 h) selectively inhibits proliferation of BCL6-dependent DLBCL cell lines (SUDHL4, SUDHL6, OCI-Ly7, Farage, DOHH2) with sub- to low-micromolar IC₅₀ values, has minimal effects on normal cell lines, and its antiproliferative activity is dependent on BCL6 expression^[1].
WK500B (2 μM; 24 h for single agent, 72 h for combinations) synergizes with PRMT5 inhibitor GSK591 (HY-100235) and EZH2 inhibitor GSK343 (HY-13500) to enhance BCL6 target gene reactivation and antiproliferative activity in SUDHL4 DLBCL cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

SUDHL4 DLBCL cells, Farage DLBCL cells, Toledo BCL6-null cells
Concentration:

2.5, 5, 10 μM
Incubation Time:

24 h
Result:

Dose-dependently reactivated expression of p53, CDKN1A, CXCR4, and CD69 at 10 μM in SUDHL4 cells and Farage cells.
Had no effect on expression of these genes at 10 μM in Toledo BCL6-null cells.

Cell Proliferation Assay^[1]

Cell Line:

DLBCL cell lines (SUDHL4, SUDHL6, OCI-Ly7, Farage, DOHH2), normal cell lines (NCM460, PNT1A, LO2, HAF), SUDHL4 cells transfected with BCL6 shRNA or scramble shRNA
Concentration:

1.25, 2.5, 5, 10 μM
Incubation Time:

72 h
Result:

Inhibited proliferation of DLBCL cell lines with IC50 values of 1.93 μM (SUDHL4), 1.10 μM (SUDHL6), 2.16 μM (OCI-Ly7), 1.19 μM (Farage), and 1.52 μM (DOHH2).
Had much weaker effects on normal cell lines, with IC50 values of 13.99 μM (NCM460), 12.61 μM (PNT1A), 21.61 μM (LO2), and 11.02 μM (HAF).
Showed little inhibitory effect across 1.25-10 μM in SUDHL4 cells with BCL6 knockdown, while dose-dependently inhibiting proliferation of scramble shRNA-transfected control cells.

Cell Cycle Analysis^[1]

Cell Line:

SUDHL4 DLBCL cells
Concentration:

2.5, 5, 10 μM
Incubation Time:

24 h
Result:

Induced dose-dependent cell cycle arrest at the S phase: 57% S phase at 2.5 μM, 63% S phase at 5 μM, and 78% S phase at 10 μM.

Apoptosis Analysis^[1]

Cell Line:

SUDHL4 DLBCL cells
Concentration:

2.5, 5, 10 μM
Incubation Time:

24 h
Result:

Induced dose-dependent apoptosis: total apoptotic cells (Annexin V-positive) were 4.81% at 2.5 μM, 25.43% at 5 μM, and 66.0% at 10 μM.

Parmacokinetics

Species	Dose	Route	T_1/2	Bioavailability
Rat^[1]	10 mg/kg	p.o.	7.93 h	82.49 %
Rat^[1]	5.0 mg/kg	i.v.	6.41 h	/

体内実験

WK500B (50 mg/kg; p.o.; daily; 12 days) significantly inhibits germinal center formation, follicular helper T cell proportions, and immunoglobulin affinity maturation in immunized C57BL/6 mice^[1].
WK500B (12.5-25 mg/kg; p.o.; daily; 18 days) potently suppresses DLBCL tumour growth in SCID mice, reactivates BCL6 target genes, reduces tumour cell proliferation, and shows no detectable toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (8-week-old male, immunized intraperitoneally with NP-CGG)^[1]
Dosage:

50 mg/kg
Administration:

p.o.; daily; 12 days
Result:

Reduced the frequency of germinal center B cells (GL7⁺FAS⁺B220⁺) to 0.4%.
Caused a profound loss of germinal centers detected by immunofluorescent staining.
Reduced the proportion of follicular helper T cells (CXCR5⁺PD1⁺CD4⁺).
Decreased titres of high-affinity NP-specific IgG1 (NP₅-BSA) and total NP-specific IgG1 (NP₂₃-BSA) in serum.

Animal Model:

SCID (6-8-week-old male, injected subcutaneously with 1×10⁷ SUDHL4 cells)^[1]
Dosage:

12.5 mg/kg; 25 mg/kg
Administration:

p.o.; daily; 18 days
Result:

Significantly suppressed tumour growth compared to controls, with reduced tumour weights and volumes.
Reactivated BCL6 target genes (p53, CDKN1A, CXCR4, CD69) in tumour tissue.
Significantly decreased Ki67-positive proliferating tumour cells.
Caused no significant changes in mouse body weight, and no obvious organ damage was detected via histology.

化学情報

CAS 番号 2253985-29-2
分子量 500.38
分子式 C₂₂H₂₃BrFN₇O
SMILES

N(C1=NC(=NC=C1F)N2C[C@H](C)N[C@H](C)C2)C3=CC=C(NC(=O)C=4N=C(Br)C=CC4)C=C3
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Xing Y, et al. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo. Cancer Lett. 2022;529:100-111. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

WK500B

Histone Methyltransferase アイソフォーム固有の製品をすべて表示

CXCR アイソフォーム固有の製品をすべて表示

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

WK500B 関連分類

HY-148640 関連分類